Sunstone et al in €20m series-B for Orphazyme

The funding round brings the total amount raised by the company to €34m, and Orphazyme will use the fresh capital to fund development of new therapeutic treatments for people suffering from severe, incurable diseases.

As part of the funding, Kurma managing partner Remi Droller will join the company's board of directors.

Sunstone's investment was made through Sunstone Life Science Ventures Fund III.

Previous funding
Orphazyme's series-A saw the company raise €14m from Sunstone Capital, Novo and Aescap Venture, the latter of which came in as a new investor. The two Danish firms had previously backed the company at the seed stage.

Company
Based in Copenhagen, Orphazyme is a biopharmaceutical business that develops medicines for the treatment of genetic diseases, with a particular focus on degenerative illnesses.

Currently, its leading drug programme is the development of a treatment for Niemann-Pick disease type C.

Founded in June 2009, the company employs 10 people.

People
Remi Droller is managing partner at Kurma Partners. Anders Hinsby is the CEO of Orphazyme.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Healthcare
• Early-stage
• Denmark
• Sunstone Capital A/S
• IDInvest Partners (AGF Private Equity)